Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B
10.3760/cma.j.issn.1674-2397.2012.04.008
- VernacularTitle:不同方案治疗慢加急性乙型肝炎肝衰竭的疗效研究
- Author:
Qiaorong GAN
;
Chen PAN
;
Rui ZHOU
;
Minghua LIN
;
Li CHEN
;
Chun LIN
;
Caiwen LIN
;
Qin LI
;
Jianrong HUANG
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Liver failure;
Antiviral agents;
Artificial liver support system
- From:
Chinese Journal of Clinical Infectious Diseases
2012;05(4):225-229
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the optimal therapy for patients with acute-on-chronic liver failure induced by hepatitis B.Methods A total of 302 patients with acute-on-chronic liver failure induced by hepatitis B in the Affiliated Infectious Diseases Hospital of Fujian Medical University were enrolled during January 2008 to January 2010.Patients were divided into group A ( medical treatment,n =57 ),group B (medical + antiviral treatment,n =80),group C ( medical + antiviral + artificial liver support system (ALSS),n =124) and group D (medical + antiviral + ALSS + traditional Chinese medicine treatment,n =41 ).Liver and renal function,prothrombin activity (PTA) and HBV DNA load were observed at the baseline,week 1,4,8,12 and the end of the treatment.All groups were followed up for 48 weeks to observe the survival rates.Kruskal-Willis H test was used to compare the efficacies in four groups,and Cox proportional hazards regression model was used for survival analysis. Results There was no difference among four groups in curative effects at week 4 ( H =3.213,P =0.360 ),but there was significant difference at week 12 (H =8.722,P =0.033).The one-year mortality rates for groups A,B,C,D were 36.84％ (21/57),32.50％ (26/80),26.61％ (33/124) and 24.39％ ( 10/41 ),respectively.The death risks of group C and D were 0.566 and 0.396 times of that in group B ( P =0.036 and 0.016).Conclusion Nucleoside analogue and ALSS plus medical treatment can effectively increase the survival rates of the patients with acute-on-chronic liver failure induced by hepatitis B.
